January 15, 2007 -- The JPMorgan meeting celebrated its 25th anniversary this year. Once known as the H&Q, JPMorgan has put its stamp on the meeting, but the inherent life-cycle of the industry and the interest of its investors has also changed the tone. Many will say biotech has matured, as if biotech is a coherent entity with its own life-cycle. Nothing could be further from the truth. Biotechnology is really a grab bag for a very diverse and largely unrelated group of technologies and their resulting commercialization waves. We look at what has worked in the past and what is working now...
